Factor XI inhibitors: what should clinicians know.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
entrez:
31
1
2023
pubmed:
1
2
2023
medline:
2
2
2023
Statut:
ppublish
Résumé
Factor XI (FXI) inhibitors were developed to address unmet needs and limitations of current anticoagulants and are currently being studied in several indications. In this paper, we review the rationale for the development of these agents and summarize what clinicians should know about drugs that target FXI. Patients with FXI deficiency may have a lower risk of venous thromboembolism and cardiovascular events and have a variable but generally mild bleeding diathesis. FXI has been proposed as a target for anticoagulants due to the potential for reduction in thrombosis with a lower risk of bleeding than current anticoagulant agents. Several classes of drugs that target FXI are under development, of which three classes (small molecule inhibitors, antisense oligonucleotides and monoclonal antibodies) have been studied in Phase II trials. At least three large Phase III trial programs are planned or are underway, and will study the efficacy and safety of FXI inhibitors in tens of thousands of patients across a variety of indications including atrial fibrillation, stroke and cancer-associated venous thromboembolism. FXI inhibitors were developed with the hope of attenuating thrombosis with reduced bleeding/impairment of haemostasis. These agents have shown promise in preliminary trials with a low rate of bleeding. Ongoing Phase III investigations will inform the utility of these agents in clinical practice.
Identifiants
pubmed: 36718618
doi: 10.1097/HCO.0000000000001015
pii: 00001573-202303000-00007
doi:
Substances chimiques
Factor XI
9013-55-2
Anticoagulants
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-93Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Braunwald E. Inhibitors of factor XI: game changers of antithrombotic therapy? Eur Heart J 2022; ehac524.
Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus 2016; 14:175–184.
Roberti R, Iannone LF, Palleria C, et al. Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. Front Pharmacol. 2021;12:684638. Available at: https://www.frontiersin.org/articles/10.3389/fphar.2021.684638 [cited 2022 Dec 1].
Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med 2014; 275:1–11.
De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J 2022; ehac464.
Xu Y, Schulman S, Dowlatshahi D, et al. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest 2017; 152:81–91.
Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 2010; 115:2569–2577.
Hayward CPM. How I investigate for bleeding disorders. Int J Lab Hematol 2018; 40:6–14.
Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14:1183–1189.
Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie 2021; 41:104–110.
Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129:1210–1215.
Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 2012; 119:2401–2408.
Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3:695–702.
Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. JASN 2016; 27:2825–2832.
Hsu C, Hutt E, Bloomfield DM, et al. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 2021; 78:625–631.
Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med 2022; 9:903029.
Poenou G, Dumitru Dumitru T, Lafaie L, et al. Factor XI inhibition for the prevention of venous thromboembolism: an update on current evidence and future perspectives. Vasc Health Risk Manag 2022; 18:359–373.
Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med 2021; 385:2161–2172.
Sharma M, Molina CA, Toyoda K, et al. Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 2022; 31:106742.
Antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. Am Coll Cardiol. Available at: https://www.acc.org/latest-in-cardiology/clinical-trials/2022/08/27/04/12/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fclinical-trials%2f2022%2f08%2f27%2f04%2f12%2faxiomatic-ssp [cited 2022 Dec 1].
Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399:1383–1390.
Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146:1196–1206.
Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute noncardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400:997–1007.
Ionis announces positive results from fesomersen development program. Ionis Pharmaceuticals, Inc. Available at: https://ir.ionispharma.com/news-releases/news-release-details/ionis-announces-positive-results-fesomersen-development-program [cited 2022 Dec 1].
Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 2020; 323:130–139.
Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med 2021; 385:609–617.
Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372:232–240.
Factor XI(a): a potential new option in antithrombotic therapy? Bayer Global. Available at: https://www.bayer.com/en/pharma/factor-xia-a-potential-new-option-in-antithrombotic-therapy [cited 2022 Dec 1].
Janssen Research & Development, LLC. A two-part, open-label, randomized, placebo-controlled crossover study to assess the reversal of the anticoagulant effects of milvexian by 4-factor prothrombin complex concentrate (4F-PCC) (Part 1) and recombinant human factor VIIa (rFVIIa) (Part 2) in healthy subjects. clinicaltrials.gov; 2022 Nov. Report No.: NCT04543383. Available at: https://clinicaltrials.gov/ct2/show/NCT04543383 [cited 2022 Nov 30].
BMS/Janssen will begin Phase III for factor XIa inhibitor milvexian by year-end. Scrip. 2022. Available at: https://scrip.pharmaintelligence.informa.com/SC146958/BMSJanssen-Will-Begin-Phase-III-For-Factor-XIa-Inhibitor-Milvexian-By-Year-End [cited 2022 Dec 1].
Anthos Therapeutics, Inc. A multicenter, randomized, open-label, blinded endpoint evaluation, Phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE. clinicaltrials.gov; 2022 Nov. Report No.: NCT05171049. Available at: https://clinicaltrials.gov/ct2/show/NCT05171049 [cited 2022 Nov 30].
Anthos Therapeutics, Inc. A multicenter, randomized, open-label, blinded endpoint evaluation, Phase 3 study comparing the effect of abelacimab vs. dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with GI/GU associated VTE. clinicaltrials.gov; 2022 Nov. Report No.: NCT05171075. Available at: https://clinicaltrials.gov/ct2/show/NCT05171075 [cited 2022 Nov 30].
Anthos Therapeutics, Inc. A multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of abelacimab (MAA868) compared with open-label rivaroxaban in patients with atrial fibrillation (AZALEA). clinicaltrials.gov; 2022 May. Report No.: NCT04755283. Available at: https://clinicaltrials.gov/ct2/show/NCT04755283 [cited 2022 Nov 30].